This trial is testing a new drug for ulcerative colitis. The study was designed to compare the new drug to a placebo, but one of the dose treatment arms is being removed from the 12-week double blind period.
- Ulcerative Colitis
1 Primary · 1 Secondary · Reporting Duration: Baseline to Week 56
5 Treatment Groups
1 of 5
BMS-986165 Dose 1
1 of 5
BMS-986165 Dose 2
1 of 5
Open label Extension, BMS-986165
1 of 5
1 of 5
50 Total Participants · 5 Treatment Groups
Primary Treatment: BMS-986165 Dose 1 · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 65 · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the scope of participation for this research?
"Affirmative. According to clinicaltrials.gov, this medical study is still recruiting participants as of November 21st 2022. The trial was posted on March 15th 2021 and requires a total of 50 enrollees from 23 distinct locations." - Anonymous Online Contributor
Has BMS-986165 Dose 1 been studied in any other contexts?
"BMS-986165 Dose 1 was initially studied in 2018 at Gastromed and subsequent trials have yielded 141 complete studies. Currently, 11 active clinical trials are underway across London, Ontario with more planned for the future." - Anonymous Online Contributor
Who is eligible to participate in the research study?
"For admittance to this study, candidates must be diagnosed with colitis or ulcerative and between the ages of 18-65. Presently, there is a need for 50 participants." - Anonymous Online Contributor
Is the patient age requirement for this clinical trial inclusive of octogenarians?
"As indicated by the criteria, only individuals aged between 18 and 65 are eligible for this trial. Conversely, there are 66 studies recruiting minors and 351 clinical trials that accept elderly patients." - Anonymous Online Contributor
Are there any healthcare facilities in this state currently conducting this trial?
"This clinical analysis is allowing individuals to enroll from Local Institution in London, Ontario; Illinois Gastroenterology Group - Arlington Heights in Arlington Heights, IL; Lubbock Digestive Disease Associates in San Diego, CA and an additional 23 sites." - Anonymous Online Contributor
Is this trial pioneering or has it been attempted before?
"BMS-986165 Dose 1 has recently been subject to 141 clinical trials, with the first study being conducted in 2018. Sponsored by Bristol-Myers Squibb, this drug was tested on 240 patients across 401 cities and 36 countries during its Phase 2 approval stage. Currently there are 11 active studies for BMS-986165 Dose 1." - Anonymous Online Contributor
Is there an opportunity to join this experiment presently?
"As seen on clinicaltrials.gov, this medical experiment is presently gathering participants and has been since March 15th 2021 when it was initially posted. The study details were most recently updated on November 21st 2022." - Anonymous Online Contributor
Has the Food and Drug Administration approved BMS-986165 Dose 1 for medical use?
"Despite the lack of evidence for efficacy, there is sufficient data to indicate BMS-986165 Dose 1's safety rating at a 2 on our scale." - Anonymous Online Contributor